🚀 VC round data is live in beta, check it out!
Xenon Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Xenon Pharmaceuticals and similar public comparables like Chongqing Zhifei, Scholar Rock, SK Biopharmaceuticals, CRISPR Therapeutics and more.
Xenon Pharmaceuticals Overview
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Founded
1996
HQ
Employees
327
Website
Sectors
Financials (LTM)
EV
$5B
Xenon Pharmaceuticals Financials
Xenon Pharmaceuticals reported last 12-month revenue of $7M and negative EBITDA of ($387M).
In the same LTM period, Xenon Pharmaceuticals generated $7M in gross profit, ($387M) in EBITDA losses, and had net loss of ($368M).
Revenue (LTM)
Xenon Pharmaceuticals P&L
In the most recent fiscal year, Xenon Pharmaceuticals reported revenue of $8M and EBITDA of ($371M).
Xenon Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $7M | XXX | $8M | XXX | XXX | XXX |
| Gross Profit | $7M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($387M) | XXX | ($371M) | XXX | XXX | XXX |
| EBITDA Margin | (5895%) | XXX | (4940%) | XXX | XXX | XXX |
| EBIT Margin | (5992%) | XXX | (4974%) | XXX | XXX | XXX |
| Net Profit | ($368M) | XXX | ($346M) | XXX | XXX | XXX |
| Net Margin | (5606%) | XXX | (4612%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Xenon Pharmaceuticals Stock Performance
Xenon Pharmaceuticals has current market cap of $5B, and enterprise value of $5B.
Market Cap Evolution
Xenon Pharmaceuticals' stock price is $57.05.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5B | $5B | -4.4% | XXX | XXX | XXX | $-3.62 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialXenon Pharmaceuticals Valuation Multiples
Xenon Pharmaceuticals trades at 747.2x EV/Revenue multiple, and (12.7x) EV/EBITDA.
EV / Revenue (LTM)
Xenon Pharmaceuticals Financial Valuation Multiples
As of April 21, 2026, Xenon Pharmaceuticals has market cap of $5B and EV of $5B.
Equity research analysts estimate Xenon Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Xenon Pharmaceuticals has a P/E ratio of (14.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV/Revenue | 747.2x | XXX | 653.8x | XXX | XXX | XXX |
| EV/EBITDA | (12.7x) | XXX | (13.2x) | XXX | XXX | XXX |
| EV/EBIT | (12.5x) | XXX | (13.1x) | XXX | XXX | XXX |
| EV/Gross Profit | 747.2x | XXX | — | XXX | XXX | XXX |
| P/E | (14.8x) | XXX | (15.7x) | XXX | XXX | XXX |
| EV/FCF | (14.7x) | XXX | (17.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Xenon Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Xenon Pharmaceuticals Margins & Growth Rates
Xenon Pharmaceuticals' revenue in the last 12 month grew by 275%.
Xenon Pharmaceuticals' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.2M for the same period.
Xenon Pharmaceuticals' rule of 40 is (9602%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Xenon Pharmaceuticals' rule of X is (9664%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Xenon Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 275% | XXX | (41%) | XXX | XXX | XXX |
| EBITDA Margin | (5895%) | XXX | (4940%) | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | 14% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (9602%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (9664%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.2M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1416% | XXX | 1062% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 4740% | XXX | 4013% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 5074% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Xenon Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Xenon Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Chongqing Zhifei | XXX | XXX | XXX | XXX | XXX | XXX |
| Scholar Rock | XXX | XXX | XXX | XXX | XXX | XXX |
| SK Biopharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CRISPR Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Shanghai RAAS | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Xenon Pharmaceuticals M&A Activity
Xenon Pharmaceuticals acquired XXX companies to date.
Last acquisition by Xenon Pharmaceuticals was on XXXXXXXX, XXXXX. Xenon Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Xenon Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialXenon Pharmaceuticals Investment Activity
Xenon Pharmaceuticals invested in XXX companies to date.
Xenon Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Xenon Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Xenon Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Xenon Pharmaceuticals
| When was Xenon Pharmaceuticals founded? | Xenon Pharmaceuticals was founded in 1996. |
| Where is Xenon Pharmaceuticals headquartered? | Xenon Pharmaceuticals is headquartered in Canada. |
| How many employees does Xenon Pharmaceuticals have? | As of today, Xenon Pharmaceuticals has over 327 employees. |
| Who is the CEO of Xenon Pharmaceuticals? | Xenon Pharmaceuticals' CEO is Ian C. Mortimer. |
| Is Xenon Pharmaceuticals publicly listed? | Yes, Xenon Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of Xenon Pharmaceuticals? | Xenon Pharmaceuticals trades under XENE ticker. |
| When did Xenon Pharmaceuticals go public? | Xenon Pharmaceuticals went public in 2014. |
| Who are competitors of Xenon Pharmaceuticals? | Xenon Pharmaceuticals main competitors are Chongqing Zhifei, Scholar Rock, SK Biopharmaceuticals, CRISPR Therapeutics. |
| What is the current market cap of Xenon Pharmaceuticals? | Xenon Pharmaceuticals' current market cap is $5B. |
| What is the current revenue of Xenon Pharmaceuticals? | Xenon Pharmaceuticals' last 12 months revenue is $7M. |
| What is the current revenue growth of Xenon Pharmaceuticals? | Xenon Pharmaceuticals revenue growth (NTM/LTM) is 275%. |
| What is the current EV/Revenue multiple of Xenon Pharmaceuticals? | Current revenue multiple of Xenon Pharmaceuticals is 747.2x. |
| Is Xenon Pharmaceuticals profitable? | No, Xenon Pharmaceuticals is not profitable. |
| What is the current EBITDA of Xenon Pharmaceuticals? | Xenon Pharmaceuticals has negative EBITDA and is not profitable. |
| What is Xenon Pharmaceuticals' EBITDA margin? | Xenon Pharmaceuticals' last 12 months EBITDA margin is (5895%). |
| What is the current EV/EBITDA multiple of Xenon Pharmaceuticals? | Current EBITDA multiple of Xenon Pharmaceuticals is (12.7x). |
| What is the current FCF of Xenon Pharmaceuticals? | Xenon Pharmaceuticals' last 12 months FCF is ($334M). |
| What is Xenon Pharmaceuticals' FCF margin? | Xenon Pharmaceuticals' last 12 months FCF margin is (5093%). |
| What is the current EV/FCF multiple of Xenon Pharmaceuticals? | Current FCF multiple of Xenon Pharmaceuticals is (14.7x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.